Featuring the author Charles Calomiris, Henry Kaufman Professor of Financial Institutions, Columbia Business School; with comments by Andrew Olmem, Partner, Venable LLP; moderated by Mark Calabria, Director, Financial Regulation Studies, Cato Institute.
In the affirmative, Roger Pilon,
Vice President for Legal Affairs, Cato Institute; in the negative, John E. Calfee,
Resident Scholar, American Enterprise Institute.
In this election year, the drug reimportation debate is heating up. Last year the House easily passed a bill that would allow Americans to buy prescription drugs abroad, where they sell at far below American prices, but the bill stalled in the Senate. This year pressure is building from governors, mayors, and ordinary citizens, many of whom are simply ignoring the current ban on importing drugs. Proponents of the bill say that free trade is likely to reduce the high prices Americans now pay for prescription drugs. Opponents raise safety concerns and add that the bill would amount to importing foreign price controls. Please join us for a timely debate on an issue that touches millions of Americans.